Nov 12
Midcap holds up to 5 mid caps above $2B, drawn from the most volatile third of the band by the model's volatility score.
Equal capital goes into every recommendation. Recommendations are published a few hours before the open and placed as market orders, so buys and sells fill at the opening price. Positions are held for 6 to 8 days. Every position carries a 25% stop-loss: if the price touches it during the day, the position is sold there, at 75% of its entry price. Reported returns are measured from those opening prices and include every stop-loss exit.
Cellebrite reports Q3 2026 results before the U.S. open on November 12, with consensus at $0.10 EPS on ~$150.3M revenue (~19% YoY growth). The key focus is whether ARR is stabilizing after August's shortfall and lowered full-year ARR guidance ($550M-$560M), plus traction for the Genesis AI suite; a beat/raise or further guidance cut would move shares sharply.
Investing.comWells Fargo and Morgan Stanley raised their price targets to $50 and $48 respectively, with consensus at Moderate Buy (10 Buy, 1 Sell). Multiple PT hikes following earnings can extend positive sentiment and attract incremental buyers.
MarketBeatVIA dropped 5.3% to $42.27 on Wednesday on volume ~78% below average, with no specific catalyst identified. The pullback reflects profit-taking after the post-earnings rally and lingering concerns over unprofitability and converting pipeline into sustainable profits, a mild near-term negative.
MarketBeatBaron's Q3 2026 investor letter disclosed that Netskope contributed 0.93% to returns at the Baron SMID Cap ETF, citing 27% year-over-year ARR growth, revenue growth of 29%, an 11-point operating margin improvement, and a raised full-year guidance. Institutional endorsement plus fundamental momentum narrative can attract momentum and fund flows in the near term.
Dealroom.coNTSK traded up about 5.18% intraday to $22.55, holding above its weekly (~$22.01) and quarterly (~$18.49) moving averages after consolidating in the $21-22 range. Technical strength and volume expansion raise the probability of a retest of the late-October high near $26.52, though weakening MACD momentum is a caveat.
CMoneyRenewed momentum in the AI complex, following stronger-than-expected results from AI infrastructure names, drove a ~7.5% single-day gain on Nov 11, pushing FROG through its prior 52-week high of $108.59 to around $111.31. The breakout removes a near-term technical hurdle and reflects continued follow-through from the Q3 beat-and-raise, though the extended move raises pullback risk.
TickeronCitizens sharply lifted its price target to $55 (from $37) while maintaining Market Outperform, citing the Q3 beat, 31% growth acceleration, and record $574M run-rate revenue. The large PT increase reinforces bullish analyst sentiment and could support near-term buying interest.
Investing.comAt the Guggenheim Healthcare Innovation Conference, Septerna management highlighted a pipeline built entirely around GPCRs and reiterated sufficient cash to fund operations, reinforcing the discovery-platform story. Conference commentary is a modest sentiment support but unlikely to be a major standalone price driver.
Investing.comInvestors bought 20,138 CLBT call options on Tuesday, roughly 2,374% above the average daily volume of 814, indicating elevated positioning and expectations into the earnings print. This raises the potential for amplified volatility around the release as positions are unwound or validated.
MarketBeatMultiple firms trimmed targets after the August guidance cut (JPMorgan to $16, Lake Street to $15, Needham to $12.50, DA Davidson $15), leaving a consensus Moderate Buy and ~$16.70 average target. Continued target revisions around the earnings print could influence near-term direction.
MarketBeatInsiders sold 196,870 shares worth about $2.8 million over the past 90 days, including CMO David Gee and CRO Marcus Jewell under pre-arranged 10b5-1 plans. While routine, the selling may weigh modestly on sentiment into earnings.
MarketBeatVia reported Q3 2026 revenue of $143.5M (+31% YoY) versus ~$138M consensus, adjusted net loss per share rounding to breakeven, and FY2026 revenue guidance of $556.7M-$558.4M above the $551.7M consensus. The beat-and-raise drove a ~14% single-day rally, signaling strong short-term positive momentum.
Via Investor Relations (Company Press Release)Management indicated Q4 2026 should be the first quarter with positive adjusted EBITDA and adjusted EPS, with Q4 adjusted EBITDA guided to $0.0-$1.5M. This profitability inflection is a key near-term narrative driver that could sustain investor optimism into the next report.
GuruFocus via Yahoo FinanceSepterna reported a Q3 2026 net loss of $26.6M (-$0.57/share) versus a $0.18 profit a year earlier, wider than the ~$0.42 loss consensus, with revenue of $18.88M below the ~$20.78M estimate. R&D spending jumped over 50% YoY to $36.6M, widening the loss and triggering a post-earnings pullback of roughly 2.2%.
SEC Filing (Form 8-K / Ex-99.1)Septerna reiterated that its ongoing Phase 1 SAD/MAD trial of SEP-479, an oral PTH1R agonist for hypoparathyroidism, will report data in Q1 2027. The reaffirmed catalyst timeline keeps investor focus on the upcoming readout, though the event itself falls outside the immediate two-week window.
SEC Filing (Form 8-K / Ex-99.1)Under the July 2025 Novo Nordisk collaboration, Novo assumed responsibility for a Septerna-delivered development candidate and initiated IND-enabling toxicology studies, with Septerna having achieved $13M in research milestones to date. The progress validates the platform and provides non-dilutive revenue, a mild positive for sentiment.
SEC Filing (Form 8-K / Ex-99.1)Royal Bank of Canada raised its price target on Netskope from $20 to $23 while keeping an "outperform" rating, implying roughly 8% upside from the prior close. Sell-side target revisions of this kind typically draw incremental buyers and reinforce the "Moderate Buy" consensus (average target ~$19.82), supporting near-term sentiment.
MarketBeatCellebrite named former Okta and SAP strategy leader Rogerio Rizzi as EVP of Corporate Strategy and Development, bringing AI, platform and M&A expertise. The appointment signals strategic focus but is unlikely to be a major standalone price driver near term.
Cellebrite News ReleasesJFrog reported Q3 2026 revenue of $179.2M (+31% YoY) and non-GAAP EPS of $0.32, beating consensus of ~$165.8M and $0.23. Cloud revenue grew 60% to $101.5M, NDR rose to 124%, and FY2026 guidance of $680-682M revenue and $1.14-1.16 EPS came in well above consensus (~$650.7M and $0.98). The beat-and-raise drove a sharp positive reaction, with shares jumping over 20% after hours and in the following session.
JFrog Investor Relations (Business Wire)On the Q3 2026 earnings call, management disclosed a $76M multiyear SaaS agreement with a leading global telecommunications company, representing 167% growth in cloud data consumption versus the prior commitment, with expansion into AI security and governance. The large deal size and expansion signal durable enterprise demand, reinforcing the positive post-earnings narrative.
The Motley Fool (Earnings Call Transcript)Septerna announced selection of oral SEP-204 as its TSHR negative allosteric modulator development candidate for Graves' disease and thyroid eye disease, with preclinical data presented at the ATA annual meeting showing restored T4 levels and reduced proptosis in animal models. The company plans to initiate a Phase 1 trial in Q1 2027, expanding the pipeline and supporting the longer-term narrative.
SEC Filing (Form 8-K)Netskope will report fiscal third quarter 2027 results (quarter ended October 31, 2026) after the close on December 2, 2026, with a call at 5:00 pm ET. The confirmed date focuses investor attention on the print; company guidance is for a Q3 loss of $0.04 to $0.03 per share, so positioning and any pre-earnings estimate revisions are the near-term drivers.
Netskope Press ReleaseMajor shareholder Lightspeed Venture Partners sold 10,621 shares at an average price of $14.90 (~$158k) in a transaction dated September 11, 2026, disclosed via SEC filing. The size is small relative to the float and the disclosure is dated, so price impact is likely limited, but continued insider selling by a large holder is a mild overhang.
MarketBeat